Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RDY 
Dr. Reddy’s Laboratories Ltd ADR (RDY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: RDY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.21
1 Year Target Price $15.21
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.83% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.41B USD | Price to earnings Ratio 19 | 1Y Target Price 15.21 |
Price to earnings Ratio 19 | 1Y Target Price 15.21 | ||
Volume (30-day avg) 4 | Beta 0.32 | 52 Weeks Range 12.18 - 16.09 | Updated Date 09/16/2025 |
52 Weeks Range 12.18 - 16.09 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 0.62% | Basic EPS (TTM) 0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.99% | Operating Margin (TTM) 20.5% |
Management Effectiveness
Return on Assets (TTM) 9.71% | Return on Equity (TTM) 17.71% |
Valuation
Trailing PE 19 | Forward PE 18.87 | Enterprise Value 12209649560 | Price to Sales(TTM) 0.04 |
Enterprise Value 12209649560 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 3.22 | Enterprise Value to EBITDA 10.99 | Shares Outstanding 832396032 | Shares Floating 591382842 |
Shares Outstanding 832396032 | Shares Floating 591382842 | ||
Percent Insiders - | Percent Institutions 13.54 |
Upturn AI SWOT
Dr. Reddy’s Laboratories Ltd ADR
Company Overview
History and Background
Dr. Reddyu2019s Laboratories Ltd was founded in 1984 by Dr. K. Anji Reddy in India. Initially focused on active pharmaceutical ingredients (APIs), it later diversified into generics and branded formulations. It has grown through strategic acquisitions and partnerships.
Core Business Areas
- Generics: Development, manufacturing, and marketing of generic pharmaceutical products across various therapeutic areas.
- Pharmaceutical Services & Active Ingredients (PSAI): Manufacturing and marketing of APIs and custom pharmaceutical services.
- Proprietary Products: Research, development, and marketing of differentiated and innovative pharmaceutical products.
- Biosimilars: Development and marketing of biosimilar versions of complex biologic drugs.
Leadership and Structure
The company is led by a board of directors and a management team. G.V. Prasad is the current Co-Chairman & Managing Director. The organizational structure is divided into global business units based on the core business areas.
Top Products and Market Share
Key Offerings
- Doxycycline: Generic antibiotic. Market share varies by region. Competitors include Teva Pharmaceuticals, Mylan (Viatris), and Sun Pharma.
- Ibuprofen: Over-the-counter pain reliever. Widely available and generic. Competitors include Johnson & Johnson (Motrin), Bayer (Aleve), and generic brands.
- Omeprazole: Generic proton pump inhibitor. Market share varies regionally. Competitors include Teva Pharmaceuticals, Mylan (Viatris), and Aurobindo Pharma.
- Rituximab biosimilar (Reditux): Biosimilar of Rituximab used for oncology and autoimmune diseases. Market share growing. Competitors include Celltrion (Truxima), Sandoz (Rixathon).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and increasing competition from generics and biosimilars. The market is expanding due to an aging population and increasing prevalence of chronic diseases.
Positioning
Dr. Reddy's is positioned as a global pharmaceutical company with a strong presence in both generics and innovative products. It benefits from a cost-effective manufacturing base in India and a growing focus on biosimilars.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be over $1 trillion. Dr. Reddy's is positioned to capture a growing share of this market through its diversified portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong presence in emerging markets
- Cost-competitive manufacturing capabilities
- Diversified product portfolio (generics, APIs, proprietary products)
- Growing biosimilars business
Weaknesses
- Dependence on generics business
- Exposure to regulatory risks in various markets
- R&D spending lower compared to larger competitors
- Geographic concentration in India
Opportunities
- Expanding biosimilars market
- Growth in emerging markets
- Strategic acquisitions and partnerships
- Increased demand for affordable medicines
Threats
- Intense competition from generic manufacturers
- Pricing pressures and reimbursement challenges
- Stringent regulatory requirements
- Patent expirations and litigation
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- AURO
Competitive Landscape
Dr. Reddy's faces competition from both generic and branded pharmaceutical companies. It competes on price, quality, and product portfolio.
Major Acquisitions
OctoPlus N.V.
- Year: 2010
- Acquisition Price (USD millions): 38
- Strategic Rationale: Acquired for its drug delivery technologies and expertise.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by expansion in emerging markets and new product launches.
Future Projections: Analyst estimates are unavailable without real-time data. Requires pulling data from financial APIs.
Recent Initiatives: Recent initiatives include investments in biosimilars, strategic acquisitions, and expansion into new markets.
Summary
Dr. Reddy's is a moderately strong player in the pharmaceutical industry, leveraging its cost-competitive manufacturing and diversified product portfolio. Its focus on biosimilars presents a significant growth opportunity, while competition and regulatory pressures remain key challenges. The company needs to closely monitor its reliance on generics and continue to invest in R&D for innovative products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Market share percentages are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dr. Reddy’s Laboratories Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2001-04-11 | CEO & Member of the Management Council Mr. Erez Israeli M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 27811 | Website https://www.drreddys.com |
Full time employees 27811 | Website https://www.drreddys.com | ||
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.